Clinical trial · Interventional
A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's
The Eliminate Trial: A Phase II/III Randomised Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's in pN0/N1 Neck for Oral Cavity Carcinomas
NCT07528495CI-TRIAL-00110583EliminaterecruitingPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study is a phase II/III prospective randomized trial designed to determine whether eliminating of post operative radiotherapy to regional lymphatics in pN0-N1oral cavity is associated with similar treatment outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| IMRT - adjuvant concurrent CRT/ RT | Radiation | — | UNRESOLVED |
| ommission of IMRT - adjuvant concurrent CRT/ RT for regional lymphatics | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm A
- description
- Post operative radiotherapy to primary tumor bed and regional lymphatics
- interventionNames
- Radiation: IMRT - adjuvant concurrent CRT/ RT
- Drug: Cisplatin
- type
- EXPERIMENTAL
- label
- Arm B
- description
- Post operative radiotherapy to primary tumor bed but omission of PORT to regional lymphatics
- interventionNames
- Radiation: ommission of IMRT - adjuvant concurrent CRT/ RT for regional lymphatics
- Drug: Cisplatin
Primary outcomes (1)
- measure
- Regional control
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 18 or above and less than 70 years 2. Stage pT1-4histological confirmed squamous cell carcinoma of oral cavity undergoing radical excision and ipsilateral/bilateral neck dissection. 3. Patient with high risk features: positive or close (≤ 5mm) margin, presence of LVI or PNI, pT3-4 4. At least one dissected hemi-neck (at least 12 nodes recovered in one dissected hemi-neck) 5. Pathological N0/ N1 neck and high risk features undergoing radiotherapy for HNSCC of the oral cavity 6. Brandwein-Gensler (BG) histological risk assessment in all patients 7. Karnofsky performance score greater or equal 70 8. Ability to complete the MD Anderson Dysphagia Inventory (MDADI) and EORTC quality of life questionnaires English or Hindi Version. 9. Timely delivery of PORT preferable within 6weeks of surgery (upto 1-2 weeks of delay beyond 6 weeks is permissible to accommodate for delayed wound healing or other logistics) 10. Written informed consent for treatment. 11. Available to attend long term follow- up Exclusion Criteria: 1. Non squamous histology 2. Presences of distant metastases 3. pT1-2 disease and no high risk features 4. Pathologically N2/N3 disease. 5. Patients that require re-irradiation for recurrent disease 6. Inadequate neck dissection (less than 12 nodes examined) 7. Primary tumor reaching midline (within 1 cm from midline) and only ipsilateral neck dissection done 8. Initiation of PORT after 8 weeks of radical surgery. 9. Previous radiotherapy to the head and neck region 10. Any invasive malignancy within previous 2 years (other than non melanomatous skin carcinoma or cervical carcinoma in situ). 11. Age \< 18 years or \> 70 years 12. Brandwein-Gensler (BG) histological risk not done
References
Publications (0)
Data not yet available
No reference posted for this study.